Core Insights - Aurora Cannabis Inc. (NASDAQ: ACB) demonstrated strong top-line growth and profitability, with positive cash flow anticipated soon [1][3] Financial Performance - The top line increased by 11%, primarily driven by robust medical cannabis demand from Germany, Poland, and Australia [2] - Gross margin expanded significantly to 61%, led by the medical business, outperforming the broader cannabis industry [2] Future Outlook - Management expects a return to positive free cash flow in the fiscal third quarter ending in December [3] - Aurora maintains a strong balance sheet with C$142 million in cash and no cannabis-related debt [3] Competitive Positioning - The re-certification of Aurora's EU-GMP and the expansion of the Leuna facility enhance visibility for sustainable growth and margin improvement [3] - ACB is trading at 0.9x forward sales and 6.5x EV/EBITDA, below peer averages, indicating attractive valuation despite strong industry positioning [4]

As filed with the Securities and Exchange Commission on March 15, 2024 Registration No. 333-277182 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ AMENDMENT NO.2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________ Akanda Corp. (Exact name of Registrant as specified in its charter) ________________________ | Ontario, Canada | 2833 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standa ...

As filed with the Securities and Exchange Commission on March 11, 2024 Registration No. 333-277182 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ AMENDMENT NO.1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________ Akanda Corp. (Exact name of Registrant as specified in its charter) ________________________ | Ontario, Canada | 2833 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standa ...